Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Safety review: squalene and thimerosal in vaccines.

Montana M, Verhaeghe P, Ducros C, Terme T, Vanelle P, Rathelot P.

Therapie. 2010 Nov-Dec;65(6):533-41. Epub 2010 Dec 23. Review.

PMID:
21176760
[PubMed - indexed for MEDLINE]
2.

Safety of thimerosal in vaccines: for whom and how many doses?

Dorea JG.

Therapie. 2011 Mar-Apr;66(2):95-6. No abstract available.

PMID:
23189333
[PubMed - indexed for MEDLINE]
3.

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.

Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A.

Vaccine. 2010 Oct 21;28(45):7331-6. doi: 10.1016/j.vaccine.2010.08.075. Epub 2010 Sep 15.

PMID:
20813217
[PubMed - indexed for MEDLINE]
4.

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.

Banzhoff A, Haertel S, Praus M.

Hum Vaccin. 2011 May;7(5):539-48. Epub 2011 May 1.

PMID:
21422814
[PubMed - indexed for MEDLINE]
Free Article
5.

Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review.

Isai A, Durand J, Le Meur S, Hidalgo-Simon A, Kurz X.

Vaccine. 2012 Nov 19;30(49):7123-9. doi: 10.1016/j.vaccine.2012.09.032. Epub 2012 Sep 26. Review.

PMID:
23022149
[PubMed - indexed for MEDLINE]
6.

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G.

Vaccine. 2009 Nov 16;27(49):6959-65. doi: 10.1016/j.vaccine.2009.08.101. Epub 2009 Sep 12.

PMID:
19751689
[PubMed - indexed for MEDLINE]
7.

Safety of adjuvanted pandemic influenza A (H1N1) 2009 vaccines.

DeStefano F, Vellozzi C, Schonberger LB, Chen RT.

BMJ. 2011 Jul 12;343:d4159. doi: 10.1136/bmj.d4159. No abstract available.

PMID:
21750073
[PubMed - indexed for MEDLINE]
8.

Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe.

Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M; VAESCO-GBS Case-Control Study Group.

BMJ. 2011 Jul 12;343:d3908. doi: 10.1136/bmj.d3908.

PMID:
21750072
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

[Position of the Drug Committee of German Physicians on vaccination against the new influenza A (H1N1)].

[No authors listed]

Kinderkrankenschwester. 2009 Nov;28(11):463-5. German. No abstract available.

PMID:
19953852
[PubMed - indexed for MEDLINE]
10.

Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.

Hwang SM, Kim HL, Min KW, Kim M, Lim JS, Choi JM, Chun BC, Kim MJ, Lee SM, Kim SY, Jeon HH.

Jpn J Infect Dis. 2012;65(3):193-7.

PMID:
22627298
[PubMed - indexed for MEDLINE]
Free Article
11.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053. Epub 2012 Apr 1.

PMID:
22472791
[PubMed - indexed for MEDLINE]
12.

Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden.

Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F.

BMJ. 2011 Oct 12;343:d5956. doi: 10.1136/bmj.d5956.

PMID:
21994316
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.

Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R.

Vaccine. 2010 Feb 17;28(7):1877-80. doi: 10.1016/j.vaccine.2009.11.077. Epub 2009 Dec 5.

PMID:
19969117
[PubMed - indexed for MEDLINE]
14.

Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study.

Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil JG, Della Cioppa G.

Am J Obstet Gynecol. 2012 Sep;207(3):177.e1-8. doi: 10.1016/j.ajog.2012.07.007. Epub 2012 Jul 16.

PMID:
22939717
[PubMed - indexed for MEDLINE]
15.

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.

Podda A.

Vaccine. 2001 Mar 21;19(17-19):2673-80.

PMID:
11257408
[PubMed - indexed for MEDLINE]
16.

Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.

Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.

J Infect Dis. 2011 Jun 15;203(12):1719-28. doi: 10.1093/infdis/jir191.

PMID:
21606530
[PubMed - indexed for MEDLINE]
Free Article
17.

Pandemic blows lid off laws limiting mercury in vaccines.

Schubert C.

Nat Med. 2010 Jan;16(1):9. doi: 10.1038/nm0110-9a. No abstract available.

PMID:
20057400
[PubMed - indexed for MEDLINE]
18.

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.

El Sahly H.

Expert Rev Vaccines. 2010 Oct;9(10):1135-41. doi: 10.1586/erv.10.111. Review.

PMID:
20923265
[PubMed - indexed for MEDLINE]
19.

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.

Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.

Pediatr Infect Dis J. 2009 Jul;28(7):563-71. doi: 10.1097/INF.0b013e31819d6394.

PMID:
19561422
[PubMed - indexed for MEDLINE]
20.

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.

Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.

Pediatrics. 2011 May;127(5):e1161-8. doi: 10.1542/peds.2010-1920. Epub 2011 Apr 4.

PMID:
21464195
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk